Precision-Panc Opens the PRIMUS-006 Pancreatic Cancer Study
June 19, 2024
June 19, 2024
GLASGOW, Scotland, June 19 (TNSres) -- The University of Glasgow issued the following news:
The University of Glasgow, alongside NHS Greater Glasgow & Clyde, has opened the PRIMUS-006 pancreatic cancer study, part of the Precision-Panc Platform.
The Phase II study will evaluate a new drug combination - gemcitabine (a chemotherapy agent), pembrolizumab (a T-cell checkpoint inhibitor) and IMM-101, a broad-spectrum immunomodulatory agent containing heat-killed, whole c . . .
The University of Glasgow, alongside NHS Greater Glasgow & Clyde, has opened the PRIMUS-006 pancreatic cancer study, part of the Precision-Panc Platform.
The Phase II study will evaluate a new drug combination - gemcitabine (a chemotherapy agent), pembrolizumab (a T-cell checkpoint inhibitor) and IMM-101, a broad-spectrum immunomodulatory agent containing heat-killed, whole c . . .